CDR2 and respiratory failure: A 48-year-old male with MSyn after treatment with the immune checkpoint inhibitor pembrolizumab for malignant melanoma, positive for anti-Yo and anti-titin antibodies, was presented to our unit with severe respiratory failure, heart failure (due to myositis, also caused by the pembrolizumab treatment), and generalized muscle weakness.